nach oben

Current HIV/AIDS Reports

Erschienen in:

18.04.2018 | The Global Epidemic (SH Vermund, Section Editor)

The Policy-Driven HIV Epidemic Among Opioid Users in the Russian Federation

verfasst von: Robert Heimer

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To explore the consequences of policies implemented in the Russian Federation in response to syndemic of HIV-1 and opioid use disorder and compare the responses to the concomitant syndemic in rural America.

Recent Findings

The syndemic spread has not been reduced by policies implemented by the Russian government, which continues to underfund harm reduction efforts to reduce HIV transmission, refuses to approve evidence-based opioid agonist treatments for opioid use disorder, and relies on criminal justice and abstinence approaches to control illicit opioids. When effective measures have been undertaken locally, the lessons learned have not been transferred to other parts of the country and local programs have been allowed to wither.

Summary

As in many parts of rural America, Russia has experienced intertwined epidemics of opioid misuse and HIV-1 that continue to expand. The expansion has been facilitated by adoption of policies that run contrary to medical and public health evidence.

Rhodes T, Ball A, Stimson GV, Kobyshcha Y, Fitch C, Pokrovsky V, et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction. 1999;94:1323–36.CrossRefPubMed

Chawla S, le Pichon T,TP, Seramy P, Nathwani A, Thomas J, et al. Global Illicit Drug Trends (2003). New York: United Nations Office on Drugs and Crime. Vienna: UN Office on Drugs and Crime; 2003. p. 15–22.

Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, et al. HIV-1 genetic subtype a/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS. 1998;12:1907–19.CrossRefPubMed

Bobkov A, Kazennova E, Selimova L, Bobkova M, Khanina T, Ladnaya N, et al. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: identification of subtype A, subtype B, and novel gagA/envB recombinants. AIDS Res Hum Retrovir. 1998;14:669–76.CrossRefPubMed

Bobkov A, Kazennova E, Khanina T, Bobkova M, Selimova L, Kravchenko A, et al. An HIV 1 subtype A strain of low genetic diversity continues to spread among injecting drug users in Russia: study of the new local outbreaks in Moscow and Irkutsk. AIDS Res Hum Retrovir. 2001;17:257–61.CrossRefPubMed

Abdala N, Carney JM, Durante AJ, Klimov N, Ostrovski D, Somlai AM, et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St. Petersburg, Russia. Int J STD AIDS. 2003;14:697–703.CrossRefPubMed

Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101:252–66.CrossRefPubMed

Dehne KL, Khodakevich L, Hamers FF, Schwärtländer B. The HIV/AIDS epidemic in eastern Europe: recent patterns and trends and their implication for policy making. AIDS. 1999;13:741–9.CrossRefPubMed

Rhodes T, Mikhailova L, Sarang A, Lowndes CM, Rylkov A, Khutorskoy M, et al. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Social Sci Med. 2003;57:39–54.CrossRef

10.

Baryshev PB, Bogachev VV, Gashnikova NM. HIV-1 genetic diversity in Russia: CRF63_02A1, a new HIV type 1genetic variant spreading in Siberia. AIDS Res Hum Retrovir. 2014;30:592–7.CrossRefPubMedPubMedCentral

11.

Abdala N, Grund J-PC, Tolstov Y, Kozlov AP, Heimer R. Can homemade injectable opiates contribute to the HIV epidemic among injection drug users in the countries of the former soviet union? Addiction. 2006;101:731–7.CrossRefPubMed

12.

Leon DA, Shkolnikov VM. Social stress and the Russian mortality crisis. JAMA. 1998;279:790–1.CrossRefPubMed

13.

Notzon FC, Komarov YM, Ermakov SP, Sempos CT, Marks JS, Sempos EV. Causes of declining life expectancy in Russia. JAMA. 1998;279:793–800.CrossRefPubMed

14.

Mendelevich V. Drug addiction treatment in Russia: no substitution therapy. HIV/AIDS Policy Law Rev. 2006;11:82–4.

15.

Anonymous. Rehabilitation required: Russia’s human rights obligation to provide evidence-based drug dependence treatment. New York: Human Rights Watch; 2007. https://www.hrw.org/report/2007/11/07/rehabilitation-required/russias-human-rights-obligation-provide-evidence-based

16.

Torban MN, Heimer R, Ilyuk R, Krupitsky EM. Practices and attitudes of addiction treatment providers in the Russian Federation. J Addiction Res Therap. 2011;2:104.

17.

Csete J. Lessons not learned: human rights abuses and HIV/AIDS in the Russian Federation. Hum Rights Watch. 2004;16(5):1–62.

18.

Anokhina IP, Pelipas VE, Tsetlin MG. Compulsory treatment: the Russian Federation’s approach. In: AI P, editor. Ethical eye: drug addiction. Strasbourg: Council of Europe Publishing; 2005. p. 65–73.

19.

Medvedev SV, Anichkov AD, Polyakov YI. Physiological mechanisms of the effectiveness of bilateral stereotactic cingulotomy against strong psychological dependence in drug addicts. Hum Physiol. 2003;29:492–7.CrossRef

20.

Wolfe D. Russia, science, and the global war on drugs. Vilnius, Eurasian Harm Reduction Network Knowledge Hub; 2016. http://www.harm-reduction.org/blog/russia-science-and-global-war-drugs.

21.

Walsh NP. Russia bans brain surgery on drug addicts. The Guardian (UK) 2002 9 August 2002.

22.

King R, Piacentini L. Ruling Russia: law, crime, and justice in a changing society. In: Pridemore WA, editor. Ruling Russia: law, crime, and justice in a changing society. Lanham: Rowman & Littlefield Publishers, Inc.; 2005. p. 261–82.

23.

Zardiashvili T. Russia in transition from recipient to donor of Global Fund grants. Nairobi; 2014. http://www.aidspan.org/gfo_article/russia-transition-recipient-donor-global-fund-grants.

24.

Broadhead RS, Volkanevsky VL, Rydanova T, Borch C, van Hulst Y, Fullerton A, et al. Peer-driven HIV interventions for drug injectors in Russia: first year impact results of a field experiment. Int J Drug Policy. 2006;17:379–92.CrossRef

25.

Sergeyev B, Oparina T, Rumyantseva TP, Volkanevskii VL, Broadhead RS, Heackathorn DD, et al. HIV prevention for drug injectors in Yaroslavl, Russia: a peer-driven intervention and needle exchange. J Drug Issues. 1999;29:777–804.CrossRef

26.

Pokrovskiy VV, Ladnaya NN, Tushina OI, Buravtsova YV. ВИЧ-ИНФЕКЦИЯ: Информационный бюллетень No 40 [HIV-infection: informational bulletin no. 40]. Moscow, RF: Federal Scientific and methodological Center for Prevention and Control of AIDS; 2015.

27.

Badrieva L, Karchevsky E. Building volunteer networks: secondary needle exchange, peer education. Kazan, RF: Project Renewal; 2001.

28.

Badrieva L, Karchevsky E, Irwin K, Heimer R. Reduced injection-related HIV-1 risk associated with participation in a harm reduction project in Kazan, Russia. AIDS Educ Prevent. 2007;41:979–99.

29.

Godlevskiy D, Volgina A, Golovin S, Girchenko P, Skvortsov A. To treat or not to treat? ARV treatment procurement and provision in Russia. St. Petersburg, RF: International Treatment Preparedness Coalition-Russia; 2012. itpcru.org/wp-content/uploads/2012/07/To_treat_or_not_to_treat_0.pdf

30.

International Treatment Preparedness Coalition. ARV procurement in Russia in 2014. Gabarone, Botswana: International Treatment Preparedness Coalition-global; 2015. http://itpcglobal.org/arv-procurement-in-russia-in-2014/.

31.

Ministry of Healthcare of the Russian Federation. Approving the State Strategy to Combat the Spread of HIV in Russia through 2020 and beyond. 2016. http://government.ru/en/docs/24983/.

32.

Cohen J. No opiate substitutes for the masses of IDUs. Science. 2010;329:165–7.CrossRefPubMed

33.

Anonymous. AIDS in Russia: immune to reason. De Economist 2016 29 Sept 2016.

34.

Hyde L. Annexation symptoms: Russian rule has cut Crimea’s drug addicts off from the treatments they depend on, with sometimes deadly results. New York and Washington: Slate; 2017.

35.

Kruptisky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgen V, et al. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St. Petersburg, Russia. Drug Alcohol Depend. 2013;132:674–80.CrossRef

36.

Kruptisky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgen V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69:973–81.CrossRef

37.

Kruptisky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abus Treat. 2006;31:319–26.CrossRef

38.

Kruptisky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–13.CrossRef

39.

Judice N. Use of naltrexone in the treatment of opioid dependence in the Russian Federation: situation analysis. Washington: Futures Group, Health Policy Project; 2012.

40.

Heimer R, Usacheva N, Barbour R, Niccolai LM, Uusküla A, Levina OS. Engagement in HIV care and its correlates among people who inject drugs in St. Petersburg, Russian Federation and Kohtla-Järve, Estonia. Addiction. 2017;112:1421–31.CrossRefPubMedPubMedCentral

41.

Vetrova MV, Aleksandrova OV, Paschenko AE, Toropov SE, Rassokhin VV, Abyshev RA, et al. Early stages of HIV treatmentcascade in people living with HIV in Saint-Petersburg, Russia. AIDS Care. 2018; Online ahead of print; https://doi.org/10.1080/09540121.2017.1417536.

42.

Anonymous. Surveillance Report: HIV/AIDS surveillance in Europe 2015. Copenhagen: European Centre for Disease Prevention and Control (ECDC) and World Health Organization (WHO) Regional Office for Europe (WHO/Europe; 2016. http://www.euro.who.int/__data/assets/pdf_file/0019/324370/HIV-AIDS-surveillance-Europe-2015.pdf?ua=1.

43.

Heimer R, Lyubimova A, Barbour R, Levina OS. Emergence of methadone as a street drug in St. Petersburg, Russia. Int J Drug Policy. 2016;27:97–104.CrossRefPubMed

44.

UN Office on Drugs and Crime. World Drug Report 2017. Vienna, Austria: UNODC; 2017. https://www.unodc.org/wdr2017/index.html

45.

MacGillis A. The last shot. New York: ProPublica; 2017. https://www.propublica.org/article/vivitrol-opiate-crisis-and-criminal-justice

46.

Heimer R, Dasgupta N, Irwin KS, Kinzly M, Phinney Harvey A, Givens A, et al. Chronic pain, addiction severity, and misuse of opioids in Cumberland County, Maine. Addict Behav. 2012;37:346–9.CrossRefPubMed

47.

Heimer R, Zhan H, Grau LE. Prevalence and experience of chronic pain in suburban drug injectors. Drug Alcohol Depend. 2015;151:92–100.CrossRefPubMedPubMedCentral

Titel: The Policy-Driven HIV Epidemic Among Opioid Users in the Russian Federation
verfasst von: Robert Heimer
Publikationsdatum: 18.04.2018
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 3/2018
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-018-0395-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Network Research Experiences in New York and Eastern Europe: Lessons for the Southern US in Understanding HIV Transmission Dynamics

Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk

NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C

Continued Interest and Controversy: Vitamin D in HIV